INDP News and Press, Indaptus Therapeutics Inc. From 04/11/24

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, was proud to unveil its poster at the 2024 Annual Meeting of the American Association for Cance...

Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows activity in M1 macrophages, natural killer cells, dendritic cells, Th1 CD4, and CD8 T cells NEW YORK, March 25, 2024 (...

“Fully Engaging The Human Immune System To Cure Disease,” Featuring CEO, Jeffrey Meckler Registration now open at INDPMarch2024.TribePublic.com NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP), a clinical stage biotech...

2024-03-14 10:09:32 ET More on Indaptus Therapeutics Seeking Alpha’s Quant Rating on Indaptus Therapeutics Historical earnings data for Indaptus Therapeutics Financial information for Indaptus Therapeutics Read the full article on Seeking Alpha ...

Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiat ing Multi-Dosing for patients with solid tumors NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “...

• Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort • Single dose cohort data expected to be published at a scientific conference in 2024 NEW YORK, Marc...

NEW YORK, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announced today that Jeffrey A. Meckler, Chief Executive Officer, and Nir Sassi, Chief Financial...

NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and upda...

NEW YORK, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biopharma company that utilizes a proprietary killed, non-pathogenic bacteria-based platform to generate stabilized packages of immune agonists to activate both innate (immediate) and adaptive...

Indaptus Therapeutics Inc. (INDP) is expected to report $-0.55 for Q3 2023